atgu.mgh.harvard.edu/people">the ATGU team in Boston
Henrike Heyne is a Visiting Researcher at FIMM, mentored by Prof. Mark Daly. She is generally interested in human genetics; with a focus on rare epilepsy disorders and aiming to bring research back to clinical application. Previously based at the University of Leipzig and the Max-Planck-Institute for Evolutionary Anthropology, she has also been working on the genetics of other brain phenotypes like obesity and animal behavior.
Juha Karjalainen is a computational scientist at the Broad Institute of MIT and Harvard and FIMM. His work is focused on large-scale analysis of genetic and biobank data in the FinnGen analysis team. Beyond crunching numbers he's interested in reporting and visualizing genetic findings effectively. Juha's educational background is engineering in Aalto University, computer science and bioinformatics in University of Helsinki and PhD in genomics in University Medical Center Groningen in the Netherlands.
Mark Daly, Ph.D. is the Director of the Institute of Molecular Medicine Finland FIMM. He was recruited from Harvard Medical School – where he was the founding chief of the Analytic and Translational Unit at the Massachusetts General Hospital from 2011 - and the Broad Institute of MIT and Harvard.
While primarily based in Finland, he retains an active role in Boston at HMS/MGH and as an Institute Member at the Broad Institute, where he is establishing a close partnership between FIMM and the Broad Institute.
Mark’s primary research focus is discovery of genes involved in human disease as a means of providing both insights for therapeutic development as well as improved diagnostics for individual patients. His lab has developed many foundational computational tools and statistical techniques in genome mapping, linkage and association, and automated interpretation of laboratory data. The lab has a significant and longstanding commitment in two major medical areas: the inflammatory bowel diseases (Crohn’s and ulcerative colitis) and neuropsychiatric disease (autism and schizophrenia) and Mark has led international consortium efforts large-scale gene mapping efforts in each of these areas – co-chairing the International IBD Genetics Consortium (